Bio-Rad Laboratories (BIO) Earnings Date & Reports

Key Takeaways

• Bio-Rad Laboratories (BIO) is scheduled to report its third-quarter 2026 results on Wednesday, November 4, 2026, after the market close.
• Wall Street consensus points to non-GAAP earnings of about $2.23 per share on revenue near $649.9 million.
• Those expectations imply modest declines versus the prior-year quarter, when the company posted non-GAAP EPS of $2.26 on revenue of $653.0 million.
• In the most recent quarter (Q2 2026), revenue of $651.0 million was roughly flat year over year, while non-GAAP EPS of $2.62 comfortably beat the $1.75 consensus.
• Investors will focus on the Life Science segment's recovery, digital PCR (dPCR) momentum, China headwinds, and any updates to full-year 2026 guidance.

Earnings Context and Why It Matters

Bio-Rad Laboratories is a leading provider of life science research and clinical diagnostics products, and its quarterly print offers a broad read on laboratory and research spending across academic, biopharma, and diagnostic end markets. The third-quarter report matters because the company has been navigating a mixed demand environment: its Clinical Diagnostics business has returned to modest growth, while the Life Science segment has faced softness in academic research. With full-year 2026 guidance calling for roughly flat currency-neutral revenue and a lower non-GAAP operating margin, this report will test whether stabilization signs seen earlier in the year are translating into durable momentum.

Earnings Expectations

For the third quarter of 2026, analysts expect Bio-Rad to report non-GAAP (a profitability measure that excludes certain one-time and non-cash items) earnings of approximately $2.23 per share on revenue of about $649.9 million. By comparison, the company reported non-GAAP EPS of $2.26 on revenue of $653.0 million in the same period a year earlier, implying a roughly 1.3% decline in earnings per share and a roughly 0.5% decline in revenue.

Those muted expectations follow a second quarter in which total revenue of $651.0 million was essentially flat as reported and down 1.9% on a currency-neutral basis. Non-GAAP EPS of $2.62 topped consensus by a wide margin, while the Life Science segment declined 5.1% currency-neutral amid academic softness and Clinical Diagnostics grew 0.3% currency-neutral. For the full year, management continues to expect currency-neutral revenue to range from a decline of about 3.0% to growth of about 0.5%, with a non-GAAP operating margin of roughly 10.0% to 12.0%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. For investors monitoring names like Bio-Rad around earnings season, tools like this can help surface context and comparable opportunities across the life sciences and diagnostics industry.

Market Reaction and Investor Sentiment

Sentiment heading into Bio-Rad's third-quarter report is cautious but watchful. The stock has traded well below its recent highs as investors weigh a multi-year stretch of uneven revenue growth, academic market softness, and persistent China headwinds. In the prior quarter, management flagged high-teens revenue declines in China and an estimated $4 million headwind for the remainder of 2026, factors that could temper enthusiasm even if headline results land in line. Key risk factors around the print include the pace of recovery in academic and government research spending, the durability of dPCR instrument demand, and whether currency-neutral revenue can stabilize near the top of the company's full-year range.

Forward Outlook and Key Factors to Monitor

Beyond the third-quarter headline numbers, investors will be listening closely for any update to Bio-Rad's full-year 2026 outlook. Management's guidance for currency-neutral revenue of roughly negative 3.0% to positive 0.5% and a non-GAAP operating margin of about 10.0% to 12.0% leaves limited room for error, so the tone around the remainder of the year will be closely scrutinized.

Several factors are worth watching. First, the trajectory of the Life Science segment matters most, since it has been the primary drag on overall growth. Early signs of stabilization in biopharma and improving academic and government end markets would be encouraging, while continued softness would raise questions about the recovery timeline. Second, digital PCR, also called dPCR (a highly sensitive technique used to detect and quantify DNA or RNA), remains a key growth driver; instrument sales grew more than 20% in the second quarter, and sustained momentum could support a longer-term growth narrative.

Finally, cost and margin execution will be in focus. The company is pursuing a restructuring program expected to deliver $30 million to $35 million in annualized net savings by the end of 2027, with a targeted 40 to 50 basis points of operating margin expansion. Investors should monitor progress on those savings, China's demand recovery, and any changes to the company's investment in Sartorius AG, which has historically contributed volatility to reported earnings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations